Michael Pearson, the outgoing chief executive at Valeant Pharmaceuticals is expected to testify next month in front of a Senate committee investigating increases in the prices of certain prescription drugs.
from WSJ.com: US Business http://ift.tt/22VhaOW
via IFTTT
No comments:
Post a Comment